Shanpeng Li

Staff Scientist

Beckman Research Institute, City of Hope
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Despite the success of the CD19 × CD3 T-cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed 267 adult patients with B-ALL treated with blinatumomab and used next-generation sequencing to identify molecular alterations. Patients received blinatumomab for relapsed/refractory (R/R) disease (n = 150) and minimal residual disease (MRD; n = 88), upfront as induction (n = 10) or as consolidation in MRD-negative state (n = 19). In the overall cohort, 50 patients (19%) had Philadelphia chromosome (Ph)–positive ALL, 80 (30%) had Ph-like ALL, 35 (13%) had TP53 mutations (TP53m), 7 (3%) had KMT2A rearrangement, and 8 (3%) had PAX5 alterations. For patients treated for R/R ALL, the overall complete remission (CR)/CR with incomplete hematological recovery (CRi) rate was 59%. Only pretreatment high disease burden (P < .01) and active EMD (P < .01) were associated with inferior CR/CRi rate. Of 169 patients in CR/CRi after blinatumomab, 79 (47%) patients relapsed, including 22 (28%) with CD19– and 54 (68%) with CD19+ relapse. In multivariable analysis, TP53m was associated with an increased risk of CD19– relapse (hazard ratio [HR], 6.84; 95% confidence interval [CI], 2.68-17.45; P < .01). Post-blinatumomab allogeneic stem cell transplantation consolidation was associated with a lower risk of CD19– relapse (HR, 0.10; 95% CI, 0.03-0.37; P < .01) and EMD relapse (HR, 0.36; 95% CI, 0.18-0.73; P < .01). In conclusion, leukemia genetics may predict patterns of blinatumomab failure, with TP53m associated with CD19– relapse.

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

Amanda Blackmon

Clinical Assistant Professor

City Of Hope National Medical Center

UNITED STATES
View details

Willy Hugo

Associate Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Jeremy G. Reynoso

University of California, Los Angeles

UNITED STATES
View details

James Wu

Assistant Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Benjamin M Ellingson

Professor

University of California, Los Angeles

UNITED STATES
View details

Vivek Sant

University of Texas Southwestern Medical Center

UNITED STATES
View details

Wolfgang Wick

University Hospital Heidelberg

GERMANY
View details

Lu Sun

Assistant Project Scientist

University of California

UNITED STATES
View details

Jose Tinajero

City of Hope

UNITED STATES
View details